...
首页> 外文期刊>Nephron >Therapeutic Mechanism of Saikosaponin-d in Anti-Thy1 mAb 1 22 3 Induced Rat Model of Glomerulonephritis
【24h】

Therapeutic Mechanism of Saikosaponin-d in Anti-Thy1 mAb 1 22 3 Induced Rat Model of Glomerulonephritis

机译:皂苷皂苷d在抗Thy1 mAb 1 22 3所致大鼠肾小球肾炎模型中的治疗机制

获取原文
获取原文并翻译 | 示例

摘要

Aims: Mesangioproliferative glomerulonephritis is a common kidney disease and at present, there is no effective treatment. Our previous studies have demonstrated that Sairei-to can significantly prevent progression of experimental glomerulonephritis in rats. Although we have reported that the active component of Sairei-to in treatment of glomerulonephritis was Saikosaponin-d (Ssd), mechanism of Ssd in prevention of mesangioproliferative glomerulonephritis progression is still unknown. Therefore, current study examines the effects of Ssd on progression of mesangioproliferative glomerulonephritis induced by anti-Thyl monoclonal antibody 1-22-3 (mAb 1-22-3) in uninephrectomized rats. Methods: Eighteen female Wistar rats first received uninephrectomy and mAb 1-22-3 injection and were then divided into 3 groups: treated daily with phosphate-buffered saline (PBS), 0.6 or 1.8 mg/kg of Ssd. Urinary protein concentration and systolic blood pressure were evaluated and the kidneys were collected and subjected to histological and immunohistological evaluation. The mRNA and protein of the kidneys were extracted and subjected to reverse transcriptase polymerase chain reaction and Western blot analysis, respectively. Results:Ssd reduced the amount of urinary protein and systolic blood pressure. Ssd administration also decreased extracellular matrix expansion, crescentic formation as well as infiltration of macrophages and CD8+ T lymphocytes. Moreover, Ssd significantly reduced expression of transforming growth factor beta 1 (TGF-beta1) and type I collagen in the kidneys. Conclusion: Ssd inhibits the progression of mesangioproliferative glomerulonephritis through reduction of the expression of TGF-beta1 and the infiltration of macrophages and CD8+ T lymphocytes.
机译:目的:血管增生性肾小球肾炎是一种常见的肾脏疾病,目前尚无有效的治疗方法。我们之前的研究表明,Sairei-to可以显着预防大鼠实验性肾小球肾炎的进展。尽管我们已经报道了Sairei-to治疗肾小球肾炎的活性成分是Saikosaponin-d(Ssd),但Ssd预防血管增生性肾小球肾炎进展的机制仍未知。因此,当前的研究检查了Ssd对未经直肠切除的大鼠中抗Thyl单克隆抗体1-22-3(mAb 1-22-3)诱发的血管增生性肾小球肾炎的影响。方法:18只Wistar雌性大鼠首先接受单肾切除术和mAb 1-22-3注射,然后分为3组:每天用磷酸盐缓冲液(PBS),0.6或1.8 mg / kg的Ssd进行治疗。评价尿蛋白浓度和收缩压,收集肾脏并进行组织学和免疫组织学评价。提取肾脏的mRNA和蛋白质,分别进行逆转录聚合酶链反应和蛋白质印迹分析。结果:Ssd降低了尿蛋白含量和收缩压。 Ssd给药还减少了细胞外基质的扩张,新月形的形成以及巨噬细胞和CD8 + T淋巴细胞的浸润。此外,Ssd显着降低了肾脏中转化生长因子β1(TGF-beta1)和I型胶原的表达。结论:Ssd通过降低TGF-β1的表达以及巨噬细胞和CD8 + T淋巴细胞的浸润来抑制血管增生性肾小球肾炎的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号